Brokerage Firm Rating on Hologic (HOLX)

Hologic (HOLX) : 16 analysts are covering Hologic (HOLX) and their average rating on the stock is 2, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 8 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Hologic (HOLX) stock is expected to deviate a maximum of $2.5 from the average target price of $42.08 for the short term period. 13 Street Experts have initiated coverage on the stock with the most promising target being $46 and the most muted being $39.


For the current week, the company shares have a recommendation consensus of Buy. Hologic (NASDAQ:HOLX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $38.70 and $38.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $38.89. The buying momentum continued till the end and the stock did not give up its gains. It closed at $38.85, notching a gain of 0.78% for the day. The total traded volume was 2,557,952 . The stock had closed at $38.55 on the previous day.

In a related news, The Securities and Exchange Commission has divulged that Crawford Sally, director of Hologic Inc, had unloaded 16,071 shares at an average price of $37 in a transaction dated on July 21, 2016. The total value of the transaction was worth $594,627.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.